Accelerating Breakthrough Discoveries into Medicines

Ferozrpapa from OptiKira talking in a lab

Scientists in lab examining solution

From research institutions to patients

BioMotiv is the mission-driven development company associated with The Harrington Project for Discovery & Development, a national initiative centered at University Hospitals Cleveland Medical Center. The company’s focus is accelerating breakthrough discoveries from research institutions into therapeutics for patients.

Led by experienced industry professionals

BioMotiv has a capable and connected management team, advisory board, and Board that oversee the development, funding, active management, and partnering of the portfolio of therapeutic products.

Pharmaceutical Expertise

Our leadership and portfolio teams are well-versed in translational science, with deep pharmaceutical experience having supported the advancement of numerous programs into clinical development and into the marketplace.

Deep Business Networks

Through their careers, the company’s leadership team and advisory board members have developed broad relationships in the investment and pharmaceutical industries that are available to be accessed by BioMotiv companies.

Partnered with leading companies

Working with
The Harrington Project
to bridge the Valley of Death


BioMotiv Opens Philadelphia Office

BioMotiv has established a Philadelphia office as it continues to grow. The office is located in The Innovation Hub, a collaborative life sciences space managed by Militia Hill Ventures, next to 30th Street...

BioMotiv Featured in Drug Discovery World

“Emerging drug discovery alliance models” discusses the current environment for early-stage drug discovery and development, highlights challenges to success, and suggests the need for allied partnerships in the drug development sphere using BioMotiv as one such model....

BioMotiv at AUTM 2018 Annual Meeting

Our colleague, Kaushik Ghosal, will be joining the Association of University Technology Managers (AUTM) 2018 Annual Meeting as a panelist at the "Creative Models to De-Risk Early Stage BioMedical Technology Development" session on February 21. He will present...